Eli Lilly's new oral obesity drug Foundayo and its phase 3 subcutaneous candidate retatrutide could challenge Novo Nordisk's position in the weight-loss market. The developments may shift investor focus and market dynamics in the pharmaceutical sector.
- Eli Lilly's Foundayo (orforglipron) is set to launch on April 6, offering an oral GLP-1 receptor agonist for weight loss without food or water restrictions.
- Foundayo's lack of dietary restrictions may enhance patient compliance compared to Novo Nordisk's Wegovy pill, which requires administration on an empty stomach.
- Eli Lilly's retatrutide, a subcutaneous triple-hormone receptor agonist in phase 3 trials, demonstrated a 28.7% average body weight loss in a 68-week trial at the 12mg dose.
- Novo Nordisk's CagriSema achieved a 23% weight loss in 84 weeks but failed to meet noninferiority compared to Lilly's tirzepatide.
- The competitive landscape in the obesity drug market could shift significantly if Eli Lilly's dual strategy with Foundayo and retatrutide proves successful.
- Novo Nordisk's next potential subcutaneous drug is still in development, which may delay its ability to respond to Eli Lilly's advancements.
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.
Share this article